Compare Core Scientific Inc (CORZ) vs Hims and Hers Health Inc (HIMS) Price & Performance

CORZ trades at $21.30, up 9.57% in the last 24 hours, showing strong momentum despite a bearish technical signal. The stock faces fundamental challenges with a net income margin of -324.9% and negative EPS misses, but recent developments include a significant partnership with AMD for up to 2.5 gigawatts of data center capacity, potentially driving future revenue growth. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a consensus price target of $35.88.

The outlook for CORZ hinges on executing its AI infrastructure strategy, with the AMD deal offering substantial upside if successfully monetized. Key risks include persistent cash burn, competitive pressures, and reliance on long-term contracts. Investors should weigh the high growth potential against the current lack of profitability and volatile stock performance.

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.